Phase 1 Safety Run-In and Phase 2 Randomized Clinical Trial of Anetumab Ravtansine and MK-3475 (Pembrolizumab) Compared to MK-3475 (Pembrolizumab) Alone for Mesothelin-Positive Malignant Pleural Mesothelioma
Phase of Trial: Phase I/II
Latest Information Update: 14 Feb 2019
At a glance
- Drugs Anetumab ravtansine (Primary) ; Pembrolizumab
- Indications Mesothelioma
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 22 Feb 2018 Planned End Date changed from 30 Sep 2021 to 2 Feb 2020.
- 08 Feb 2018 Planned primary completion date changed from 30 Sep 2021 to 2 Feb 2020.